Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016

被引：1600

作者：

Dorsey, E. Ray ^{[1
]}

Elbaz, Alexis ^{[2
]}

Nichols, Emma ^{[3
]}

Abd-Allah, Foad ^{[4
]}

Abdelalim, Ahmed ^{[4
]}

Adsuar, Jose C. ^{[5
]}

Ansha, Mustafa Geleto ^{[7
]}

Brayne, Carol ^{[8
]}

Choi, Jee-Young J. ^{[9
]}

Collado-Mateo, Daniel ^{[6
,10
]}

Dahodwala, Nabila ^{[11
]}

Huyen Phuc Do ^{[12
]}

Edessa, Dumessa ^{[13
]}

Endres, Matthias ^{[15
]}

Fereshtehnejad, Seyed-Mohammad ^{[16
,17
]}

Foreman, Kyle J. ^{[3
,18
]}

Gbetoho Gankpe, Fortune ^{[19
,20
]}

Gupta, Rahul ^{[21
,22
,23
]}

Hankey, Graeme J.

Hay, Simon I. ^{[3
]}

Hegazy, Mohamed I. ^{[4
]}

Hibstu, Desalegn T. ^{[24
]}

Kasaeian, Amir ^{[25
]}

Khader, Yousef ^{[26
]}

Khalil, Ibrahim ^{[3
]}

Khang, Young-Ho ^{[27
]}

Kim, Yun Jin ^{[28
]}

Kokubo, Yoshihiro ^{[29
]}

Logroscino, Giancarlo ^{[30
]}

Massano, Joao ^{[31
,33
]}

Ibrahim, Norlinah Mohamed ^{[34
]}

Mohammed, A. Mohammed ^{[35
,36
]}

Mohammadi, Alireza ^{[37
]}

Moradi-Lakeh, Maziar ^{[38
]}

Naghavi, Mohsen ^{[3
]}

Binh Thanh Nguyen ^{[12
]}

Nirayo, Yirga Legesse ^{[39
]}

Ogbo, Felix Akpojene ^{[40
]}

Owolabi, Mayowa Ojo ^{[41
]}

Pereira, David M. ^{[32
]}

Postma, Maarten J. ^{[42
]}

Qorbani, Mostafa ^{[43
]}

Rahman, Muhammad Aziz ^{[44
,45
]}

Roba, Kedir T. ^{[14
]}

Safari, Hosein ^{[46
]}

Safiri, Saeid ^{[47
]}

Satpathy, Maheswar ^{[48
]}

Sawhney, Monika ^{[49
]}

Shafieesabet, Azadeh ^{[50
]}

Shiferaw, Mekonnen Sisay ^{[13
]}

机构：

[1] Univ Rochester, Dept Neurol, Rochester, NY 14642 USA

[2] Hop Paul Brousse, INSERM, U1018, CESP, F-94807 Villejuif, France

[3] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA

[4] Cairo Univ, Dept Neurol, Cairo, Egypt

[5] Univ Extremadura, Fac Sport Sci, Badajoz, Spain

[6] Univ Extremadura, Dept Didact Expres Mus Plast & Corporal, Badajoz, Spain

[7] Debre Berhan Univ, Publ Hlth, Debre Berhan, Ethiopia

[8] Univ Cambridge, Publ Hlth & Primary Care, Cambridge, England

[9] Seoul Natl Univ Hosp, Biochem, Biomed Sci, Seoul, South Korea

[10] Univ Autonoma Chile, Fac Educ, Talca, Chile

[11] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA

[12] Duy Tan Univ, Inst Global Hlth Innovat, Hanoi, Vietnam

[13] Haramaya Univ, Sch Pharm, Harar, Ethiopia

[14] Haramaya Univ, Sch Nursing & Midwifery, Harar, Ethiopia

[15] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany

[16] McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ, Canada

[17] Karolinska Inst, Dept Neurobiol, Care Sci & Soc, Huddinge, Sweden

[18] Imperial Coll London, Dept Epidemiol & Biostat, London, England

[19] Fac Med & Pharm Fez, Neurosurg Dept, Fes, Morocco

[20] Lab Etud & Rech Act Sante Leras Afrique, Noncommunicable Dis Dept, Porto Novo, Benin

[21] West Virginia Bur Publ Hlth, Charleston, WV USA

[22] West Virginia Univ, Sch Publ Hlth, Hlth Policy Management & Leadership, Morgantown, WV USA

[23] Univ Western Australia, Med Sch, Perth, WA, Australia

[24] Hawassa Univ, Dept Reprod Hlth, Hawassa, Ethiopia

[25] Univ Tehran Med Sci, Hematol Malignancies Res Ctr, Hematol Oncol & Stem Cell Transplantat Res Ctr, Tehran, Iran

[26] Jordan Univ Sci & Technol, Publ Hlth & Community Med, Alramtha, Jordan

[27] Seoul Natl Univ, SNU Med Res Ctr, Inst Hlth Policy & Management, Dept Hlth Policy & Management,Coll Med, Seoul, South Korea

[28] Xiamen Univ Malaysia, Sch Med, Sepang, Malaysia

[29] Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka, Japan

[30] Univ Bari Aldo Moro, Bari, Italy

[31] Univ Porto, Dept Clin Neurosci & Mental Hlth, Fac Med, Porto, Portugal

[32] Univ Porto, REQUIMTE LAQV, Lab Farmacognosia, Dept Quim,Fac Farm, Porto, Portugal

[33] Univ Porto, Porto, Portugal

[34] Univ Kebangsaan Malaysia, Med Ctr, Dept Med, Bandar Tun Razak, Malaysia

[35] Jigjiga Unviers, Dept Publ Hlth, Jigjiga, Ethiopia

[36] Univ Sydney, Sydney, NSW, Australia

[37] Baqiyatallah Univ Med Sci, Neurosci Res Ctr, Tehran, Iran

[38] Iran Univ Med Sci, Prevent Med & Publ Hlth Res Ctr, Community & Family Med, Tehran, Iran

[39] Mekelle Univ, Dept Clin Pharm, Mekelle, Ethiopia

[40] Western Sydney Univ, Penrith, NSW, Australia

[41] Univ Ibadan, Dept Med, Ibadan, Nigeria

[42] Univ Groningen, Univ Med Ctr Groningen, Dept Pharm, Groningen, Netherlands

[43] Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, Iran

[44] La Trobe Univ, Austin Clin Sch Nursing, Heidelberg, Vic, Australia

[45] Deakin Univ, Sch Med, Waurn Ponds, Vic, Australia

[46] Ahvaz Jundishapur Univ Med Sci, Dept Neurosurg, Ahvaz, Iran

[47] Maragheh Univ Med Sci, Sch Nursing & Midwifery, Managerial Epidemiol Res Ctr, Dept Publ Hlth, Maragheh, Iran

[48] Utkal Univ, Ctr Adv Study Psychol, Bhubaneswar, India

[49] Univ North Carolina Charlotte, Dept Publ Hlth Sci, Charlotte, NC USA

[50] NYU, Langone Med Ctr, New York, NY USA

来源：

LANCET NEUROLOGY | 2018年 / 17卷 / 11期

基金：

比尔及梅琳达.盖茨基金会;

关键词：

DEATH CERTIFICATES; TIME TRENDS; PREVALENCE; HEALTH; ASSOCIATION; DISORDERS; COUNTRIES; MORTALITY; EXPOSURE; SMOKING;

D O I：

10.1016/S1474-4422(18)30295-3

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

100204 [神经病学];

摘要：

Background Neurological disorders are now the leading source of disability globally, and ageing is increasing the burden of neurodegenerative disorders, including Parkinson's disease. We aimed to determine the global burden of Parkinson's disease between 1990 and 2016 to identify trends and to enable appropriate public health, medical, and scientific responses. Methods Through a systematic analysis of epidemiological studies, we estimated global, regional, and country-specific prevalence and years of life lived with disability for Parkinson's disease from 1990 to 2016. We estimated the proportion of mild, moderate, and severe Parkinson's disease on the basis of studies that used the Hoehn and Yahr scale and assigned disability weights to each level. We jointly modelled prevalence and excess mortality risk in a natural history model to derive estimates of deaths due to Parkinson's disease. Death counts were multiplied by values from the Global Burden of Disease study's standard life expectancy to compute years of life lost. Disability-adjusted life-years (DALYs) were computed as the sum of years lived with disability and years of life lost. We also analysed results based on the Socio-demographic Index, a compound measure of income per capita, education, and fertility. Findings In 2016, 6.1 million (95% uncertainty interval [ UI] 5.0-7.3) individuals had Parkinson's disease globally, compared with 2.5 million (2.0-3.0) in 1990. This increase was not solely due to increasing numbers of older people, because age-standardised prevalence rates increased by 21. 7% (95% UI 18.1-25.3) over the same period (compared with an increase of 74.3%, 95% UI 69. 2-79.6, for crude prevalence rates). Parkinson's disease caused 3.2 million (95% UI 2. 6-4.0) DALYs and 211 296 deaths (95% UI 167 771-265 160) in 2016. The male-to-female ratios of agestandardised prevalence rates were similar in 2016 (1.40, 95% UI 1 .36-1.43) and 1990 (1.37, 1.34-1.40). From 1990 to 2016, age-standardised prevalence, DALY rates, and death rates increased for all global burden of disease regions except for southern Latin America, eastern Europe, and Oceania. In addition, age-standardised DALY rates generally increased across the Socio-demographic Index. Interpretation Over the past generation, the global burden of Parkinson's disease has more than doubled as a result of increasing numbers of older people, with potential contributions from longer disease duration and environmental factors. Demographic and potentially other factors are poised to increase the future burden of Parkinson's disease substantially. (C) 2018 The Author(s). Published by Elsevier Ltd.

引用

页码：939 / 953

页数：15

共 47 条

[1]

Time trends of incidence of age-associated diseases in the US elderly population: medicare-based analysis [J].

Akushevich, Igor ;

Kravchenko, Julia ;

Ukraintseva, Svetlana ;

Arbeev, Konstantin ;

Yashin, Anatoly I. .

AGE AND AGEING, 2013, 42 (04) :494-500

[2]

Case ascertainment uncertainties in prevalence surveys of Parkinson's disease [J].

Anderson, DW ;

Rocca, WA ;

de Rijk, MC ;

Grigoletto, F ;

Melcon, MO ;

Breteler, MMB ;

Maraganore, DM .

MOVEMENT DISORDERS, 1998, 13 (04) :626-632

[3]

[Anonymous], 2016, NEUROLOGY, DOI DOI 10.1212/WNL.0000000000002350

[4]

[Anonymous], J EPIDEMIOLOGY COMMU

[5]

[Anonymous], EPIDEMIOLOGY CHRONIC

[6]

[Anonymous], 2017, LANCET, DOI DOI 10.1016/S0140-6736(17)32152-9

[7]

[Anonymous], JAMA

[8]

Projected Numbers of People With Movement Disorders in the Years 2030 and 2050 [J].

Bach, Jan-Philipp ;

Ziegler, Uta ;

Deuschl, Guenther ;

Dodel, Richard ;

Doblhammer-Reiter, Gabriele .

MOVEMENT DISORDERS, 2011, 26 (12) :2286-2290

[9]

Barber RM, 2017, LANCET, V390, P231, DOI [10.1016/s0140-6736(17)30818-8, 10.1016/S0140-6736(17)30818-8]

[10]

Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses [J].

Bellou, Vanesa ;

Belbasis, Lazaros ;

Tzoulaki, Ioanna ;

Evangelou, Evangelos ;

Ioannidis, John P. A. .

PARKINSONISM & RELATED DISORDERS, 2016, 23 :1-9

← 1 2 3 4 5 →